Biomarker testing is crucial for personalized oncology care, aiding in risk stratification and treatment decisions, but faces ...

The FDA granted orphan drug designation to CTD402 for relapsed or refractory T-cell acute lymphoblastic leukemia and ...

Researchers have found a reliable way to grow helper T cells from stem cells, solving a major challenge in immune-based ...

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets TRBC2-positive T-cell cancers, expanding a precision approach they established ...

Lung cancer varies widely from patient to patient, and that diversity makes it hard to find effective treatments. Researchers ...

Scientists have discovered that T cell receptors activate through a hidden spring-like motion that had never been seen before. This breakthrough may help explain why immunotherapy works for some ...

Scientists have demonstrated a dependable method to generate large numbers of helper T cells from stem cells, removing a long-standing obstacle that has limited immune-based cancer treatments. The ...

The early-stage clinical trial marks the first U.S. testing of Alveltamig, an immunotherapy designed to help the immune system better recognize and respond to small cell lung cancer. The study aims to ...